Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Names President of Astellas US Technologies | Contract Pharma
Breaking News, Promotions & Moves

Astellas Names President of Astellas US Technologies

John DeMay will be responsible for collaboration and cooperation across pharmaceutical technology divisions

Astellas has appointed John DeMay president, Astellas US Technologies, Inc. (AUST). He will be responsible for promoting collaboration and cooperation across pharmaceutical technology divisions functions in the Americas. He will also serve as the site manager for AUST based in Northbrook and will represent AUST in various Americas management activities. Mr. DeMay will also continue in his role as head of project and product management group.

“John’s background and broad experience in this area will help him meet the challenges of this new role, while continuing to grow the strong partnerships that exist within AUST and between AUST and its collaborators,” said Katsutoshi Nakamura, head of project and product management within pharmaceutical technology, AUST. “He is dedicated to assuring stable global supply of clinical and commercial products for patients.”

Previously, Mr. DeMay served as executive director, pharmaceutical technology management for AUST.  He joined Astellas in 2002 as an associate director of technical services and later served as director and senior director of the CMC technology group within U.S. pharmaceutical technology management.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters